glp 1 with blue cross blue shield Why we are changing coverage of GLP-1 drugs for weight loss Blue Cross Blue Shield of

Gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation, are common with GLP-1 receptor agonists

NICE guidance for the use of GLP-1 receptor agonists in type 2 diabetes (NG28) and for weight management (the current NICE Technology Appraisal for semaglutide 2

Researchers are still exploring the link between protein and GLP-1 production, and more human studies are ultimately needed

Overall, payers will need to take a collaborative and cooperative approach across provider, PBM, manufacturer and third-party condition management program stakeholders to effectively expand coverage to members

Clinicians will also evaluate a patient for medical conditions that might make weight loss more challenging, such as perimenopause or hypothyroidism, which is underactive thyroid